期刊文献+

GDP方案联合放疗治疗难治性NHL疗效及毒性分析 被引量:2

The efficacy and toxicities of GDP protocol combined with radiotherapy for refractory Non-hodgkin'slymphoma
下载PDF
导出
摘要 目的观察GDP方案联合放疗治疗难治性非霍奇金淋巴瘤(NHL)疗效及毒性反应。方法CHOP方案化疗3周期未获完全缓解的NHL患者43例,随机分成GDP方案治疗组和GDP方案联合放疗组。观察两组的肿瘤有效率、白细胞和血小板抑制率、治疗后白细胞和血小板的恢复时间。结果化疗组和化疗联合放疗组总有效率分别为22.7%、66.7%,差异有极显著性(x2=8.41,P〈0.01);3度以上白细胞抑制率分别为22.7%、52.4%,差异有显著性(x2=4.04,P〈0.05);3度以上血小板抑制率分别为31.8%、42.9%,差异无显著性(x2=0.56,P〉0.05);C—CSF治疗后白细胞恢复时间分别为(3.6±1.5)天、(5.7±2.3)天,差异有极显著性(x2=3.563,P〈0.01);IL—11治疗后血小板恢复时间分别为(6.5±2.6)天、(12.3±4.1)天,差异有极显著性(t=-5.567,P〈0.01)。结论GDP方案联合放疗可提高难治性NHL的肿瘤有效率,但3度以上白细胞抑制率增加、白细胞和血小板的恢复时间延长。 Objective To investigate the efficacy and toxicities of GDP protocol combined with radiotherapy for refractory Non-hodgkin's lymphoma ( NHL ). Methods 43 patients with NHL who had received CHOP protocol for three cycles but not achieved complete response were randomly assigned to group with GDP alone or group with GDP plus radiotherapy. The response rate, rates of platelet and leukocyte inhibition, and recovery time to platelet and leukocyte after treatment were observed. Resuits Tthe overall response rate (PR+CR) was 22.7% for the group with GDP alone and 66.7% for the group with GDP plus radiotherapy ( X2= 8.41, P〈 0.01) leukocyte inhibition rate of grade Ⅲor above was 22.7% and 52.4%, respectively ( X 2= 4.04, P 〈 0.05 ); platelet inhibition rate of grades m or above was 31.8% and 42.8% ( X 2= 0.56, P 〉 0.05 );, recovery time to platlet after therapy with C-CSF was ( 3.6 ±1.5 ) days and ( 5.7 ±2.3 ) days, respectively ( t= 3.563, P 〈 0.01 ); and recovery time to platelet after treatment with IL-11 was ( 6.5 ±2.6 ) days and ( 12.3 ±4.1 ) days ( t = 5.567, P 〈 0. 01 ). Conclusions GDP protocol combined with radiotherapy can enhance the overall response rale in patients with refractory Non-hodgkin's lymphoma. However, leukocyte inhibition rate of grade Ⅱor above increases and recovery time to platelet and leukocyte prolongs.
出处 《国际医药卫生导报》 2011年第19期2339-2342,共4页 International Medicine and Health Guidance News
基金 广东省科技计划项目(20098030801362)
关键词 难治性NHL GDP方案 放疗 Refractory Non-hodgkin's lymphoma GDP protocol Radiotherapy
  • 相关文献

参考文献11

  • 1Pfreundschuh M, Schubert J, Ziepert M, et al. Six ver- sus eight cycles of bi-weekly chop-14 with or without rituximab in elderly patients with CD20+ B-cell lymphoms: a randomized controlled trial ( RICOVER- 60 )[J]. Lancet Oncol, 2008, 9 ( 2 ). 105-116.
  • 2Liauw SL, Yeh AM, Morris CG, et al. Whole-abdomen radiotherapy for non-Hodgkin' s lymphoma using twice-daily fractionation[J]. Int J Rdaiat Oncol Biol Phys,2006, 66 ( 5 ):. 1440-1445.
  • 3Kewalramani T, Zelenetz AD, Hedrick EE, et al. High- dose chemoradiotherapy and autologous stem cell trans- plant for patients with pr/mary refractory aggressive non- Hodgkin' s lymphoma: an intention-to-treat analysis [J]. Blood, 2000, 96 ( 7 ): 2399-2404.
  • 4Mey U J, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relased or refactory aggressive non-Hodgkin' s lymphoma[J]. Cancer invest, 2006, 24 ( 6 ) 593-600.
  • 5Grump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin' s lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group ( NCIC-CTG ) [J]. Cancer, 2004, 101: 1834-1842.
  • 6Salman H, Prez A. Phase II trials of infusional cyclophamide, idambicin, and etoposide in poor prog- nosis non-Hodgkin' s lymphoma[J]. Am J Clin Oncol, 2003, 26 ( 4 ):. 338-347.
  • 7Nabhana C, Davis N, Bitran JD, et al. Efficacy and safety of clofarabine in relapsed and/or refractory non- Hodgkin lymphoma, including rituximab-refractory patients[J]. Cancer, 2011, 117 ( 7 ):. 1490-1497.
  • 8Kelsey CR, Beaven AW, Diehl LF, et al. Radiation therapy in the managment of diffuse large B-cell lymphoma: still relevant[J]. Oncology, 2010, 24( 13 ). 1204-1212.
  • 9Grange F, D 'lincan M, Ortonne N, et al. Management of cutaneous B-cell lymphoma:recommemdations of the French cutaneous lymphoma study group[J]. Ann dermatol Venerol 2010, 137 ( 8-9 ): 523-531.
  • 10Au Wy. Current management of nasal NK/T-cell lym- phoma [J]. Oncology, 2010, 24 (4 ). 352-358.

同被引文献24

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部